Provider
QP81-23 Update: Medical Drug Update for Tofersen (Qalsody), Delandistrogene Moxeparvovec (Elevidys), and Donislecel (Lantidra)
Program effective Date: Oct 11, 2023
Search Results
Displaying 1381 - 1390 of 4139 results
Provider
QP82-23 Commercial Pharmacy Benefit Exclusion for Beyfortus™, Daxxify®, Izervay™, and Veopoz™
Program effective Date: Oct 11, 2023
Provider
QP83-23 Commercial Pharmacy Benefit Exclusion for Budesonide-Formoterol Aerosol Inhaler and Tiotropium Bromide Inhalation Capsule
Program effective Date: Oct 11, 2023
Provider
QP84-23 Commercial Pharmacy Benefit Update: Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective December 1, 2023
Program effective Date: Oct 11, 2023
Provider
QP85-23 MHCP Pharmacy Benefit Exclusion for Beyfortus™, Daxxify®, Elrexfio™, Izervay™, Talvey™, and Veopoz™
Program effective Date: Oct 11, 2023
Provider
QP86-23 MHCP Pharmacy Benefit Update: New and Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective November 1, 2023
Program effective Date: Oct 11, 2023
Provider
QP87-23 Availity Essentials Updated Claim Entry Forms
Program effective Date: Oct 11, 2023
Prescription & Pharmacy
Provider
policyii-174-med-drug-eval-process-list-2023-1001.pdf
Prescription & Pharmacy
Provider
bc-com-med-adv-preferred-drug-list-2023-1002.pdf